Shares of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reached a new 52-week high on Wednesday . The stock traded as high as $15.45 and last traded at $15.29, with a volume of 850,561 shares changing hands. The stock had previously closed at $15.10.

IRWD has been the topic of several research reports. Wedbush reaffirmed a “neutral” rating and set a $10.00 price objective on shares of Ironwood Pharmaceuticals in a research report on Thursday, July 21st. Zacks Investment Research cut Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Cowen and Company reissued a “buy” rating on shares of Ironwood Pharmaceuticals in a research report on Thursday, May 26th. JPMorgan Chase & Co. boosted their price target on Ironwood Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Finally, Leerink Swann reissued a “market perform” rating and issued a $14.00 price target (up from $10.00) on shares of Ironwood Pharmaceuticals in a research report on Monday, August 8th. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $15.20.

The company’s market capitalization is $2.22 billion. The firm’s 50 day moving average price is $13.78 and its 200 day moving average price is $12.35.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/ironwood-pharmaceuticals-inc-irwd-sets-new-12-month-high-at-15-45.html

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.01. Ironwood Pharmaceuticals had a negative net margin of 45.21% and a negative return on equity of 94.75%. The business had revenue of $54.40 million for the quarter, compared to the consensus estimate of $54.49 million. During the same quarter in the prior year, the business posted ($0.34) earnings per share. Ironwood Pharmaceuticals’s revenue for the quarter was up 96.4% on a year-over-year basis. Equities research analysts predict that Ironwood Pharmaceuticals Inc. will post ($0.75) earnings per share for the current year.

In other news, Director Lawrence S. Olanoff sold 3,200 shares of the stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $13.72, for a total transaction of $43,904.00. Following the transaction, the director now directly owns 29,305 shares in the company, valued at $402,064.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 7.17% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in IRWD. Dynamic Technology Lab Private Ltd acquired a new position in Ironwood Pharmaceuticals during the second quarter worth about $144,000. Parametrica Management Ltd acquired a new position in Ironwood Pharmaceuticals during the second quarter worth about $150,000. Prudential Financial Inc. increased its position in Ironwood Pharmaceuticals by 12.5% in the second quarter. Prudential Financial Inc. now owns 12,614 shares of the company’s stock worth $165,000 after buying an additional 1,400 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Ironwood Pharmaceuticals during the second quarter worth about $180,000. Finally, Amalgamated Bank increased its position in Ironwood Pharmaceuticals by 3.0% in the second quarter. Amalgamated Bank now owns 13,668 shares of the company’s stock worth $182,000 after buying an additional 397 shares in the last quarter. Hedge funds and other institutional investors own 93.96% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.

5 Day Chart for NASDAQ:IRWD

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.